Binosto, which provides fracture-risk reduction at the hip & spine, is claimed to be the first and only buffered solution used in the treatment of osteoporosis.
EffRx chairman and CEO Christer Rosen said, "We are pleased to initiate a partnership with Ahn-Gook who has a dynamic and outstanding sales force, and we are convinced that Ahn-Gook becomes a new strong player in the Korean osteoporosis market."
Ahn-Gook president & CEO Jin Auh said that the Korean market is worth $140m, while bisphosphonates account for more than 90% of the market and the company hopes that with Binosto, it would be able to tap the Korean market.
Binosto (buffered alendronate sodium 70mg), which is an effervescent tablet for oral solution, has been approved in the US, Europe and Australia markets, is likely to be registered in Korea in 2014 and launched in the same year.
Based in Korea, Ahn-Gook Pharma manufactures an array of medicines, which include respiratory agents, gastrointestinal agents, anti-inflammatories, analgesics, ophthalmics and circulatory system agents.